扶正消积方联合化疗对晚期乳腺癌患者生活质量及血清肿瘤标志物的影响

目的:观察扶正消积方联合化疗治疗晚期乳腺癌患者近期疗效及对生活质量、血清肿瘤标志物水平的影响。方法:将48例晚期乳腺癌患者随机分为治疗组和对照组各24例,均予卡培他滨加长春瑞滨方案化疗,治疗组在化疗基础上加服中药扶正消积方。2组患者均于完成2个周期后4周观察近期疗效、生活质量、血清肿瘤标志物水平变化。结果:(1)近期疗效方面:有效率(RR),治疗组为50.0%,对照组为41.7%,2组比较者无统计学意义(P>0.05);但疾病控制率(DCR)治疗组为87.5%,对照组为58.3%,2组比较,有显著性差异(P<0.05)。(2)生活质量变化:治疗组和对照组有效率分别为87.5%和54.2%,2组比较,有显著性差异(P<0.05)。(3)血清肿瘤标志物方面:2组CEA、CA 125、CA 15-3治疗前、后比较有显著性差异,治疗组治疗后三者均较对照组显著下降(P<0.05)。结论:扶正消积方联合化疗能提高晚期乳腺癌患者的生活质量,降低血清肿瘤标志物水平,增强疗效,延长生存时间。

Study on the Effect of Fuzheng Xiaoji Recipe Combined with Chemotherapy on the Life Quality and Serum Tumor Markers of Late Breast Cancer Patients

Objective:To observe the effect of Fuzheng Xiaoji recipe combined with chemotherapy on the life quality and serum tumor markers of late breast cancer patients.Methods:48 patients were randomly divided into one treatment group and one control group,24 patients per group.The patients of the two groups are treated with capecitabine and vinorelbine,but the patients in the treatment group were added with Fuzheng Xiaoji recipe.The recent efficacy,life quality and serum tumor markers of the patients in the two groups were observed in four weeks.Results:A.in short-term effect:the response rate(RR)of treatment group was 50.0% while that of the control group was 41.7% and the comparison of the two groups showed no statistical significance(P>0.05).The disease control rate(DCR) of the treatment group was 87.5% while that of the control group was 58.3%,and the comparison showed significant differences(P<0.05).B.in the changes of the life quality:the effective rates of the treatment group and control group were 87.5% and 54.2% respectively,showing significant differences(P<0.05).C.serum tumor markers:CEA,CA 125,CA 15-32 of the two groups showed more significant differences before and after the treatment.The three markers of the treatment group were remarkably lower than that of the control group(P<0.05).Conclusion:Fuzheng Xiaoji recipe combined with chemotherapy can improve the life quality of the late breast cancer patients and reduce their serum tumormarkers and enhance their efficacy and prolong their survival time.